Trial Profile
Phase 1 a/b Study of C31510 Alone and in Combination with Fludarabine and Cytarabine in Patients with Relapsed or Refractory Leukemia, High-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 21 Jul 2014
Price :
$35
*
At a glance
- Drugs Ubidecarenone (Primary) ; Cytarabine; Fludarabine
- Indications Leukaemia; Myelodysplastic syndromes; Myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Berg Pharma
- 21 Jul 2014 New trial record